Evaluation of FGFR Alteration Status in Urothelial Tumors

Veronika Bahlinger; Markus Eckstein; Arndt Hartmann; Robert Stöhr

doi:10.1007/978-1-0716-3291-8_17

Evaluation of FGFR Alteration Status in Urothelial Tumors

Methods Mol Biol. 2023:2684:283-291. doi: 10.1007/978-1-0716-3291-8_17.

Authors

Veronika Bahlinger¹, Markus Eckstein², Arndt Hartmann², Robert Stöhr²

Affiliations

¹ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. [email protected].
² Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

PMID: 37410241
DOI: 10.1007/978-1-0716-3291-8_17

Abstract

FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen^® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit.

Keywords: FGFR testing; Inhibitor; QIAGEN therascreen® FGFR RGQ RT-PCR Kit; SNaPshot analysis; Targeted therapy; Urothelial carcinoma.

MeSH terms

Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / genetics
Humans
Point Mutation
Protein Kinase Inhibitors / therapeutic use
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / genetics
Urologic Neoplasms* / drug therapy
Urologic Neoplasms* / genetics

Substances

Protein Kinase Inhibitors